Navigating Your Treatment Options for FSGS
At a Glance
FSGS treatment depends on why the kidney filters are damaged. Primary FSGS with heavy protein loss may require steroids or other medicines that calm the immune system, while secondary and genetic forms are usually managed by treating the cause and protecting kidney function.
Treatment for Focal Segmental Glomerulosclerosis (FSGS) is not “one size fits all.” Because FSGS is a pattern of injury with many different causes, your treatment plan depends entirely on why your kidney filters are being damaged [1], as well as your nephrotic syndrome status, eGFR, severity, and other health conditions. The KDIGO 2021 guidelines—the global standard for kidney care—emphasize that the first step in treatment is correctly identifying the cause to avoid unnecessary or harmful medications [2].
Treating Primary FSGS
In Primary FSGS, it is proposed that an unidentified circulating factor in the blood is actively injuring the kidneys [3]. Because this is an active, aggressive process, treatment focuses on calming the immune system (immunosuppression), particularly for patients with nephrotic syndrome.
- First-Line: Glucocorticoids (Steroids): High-dose steroids, such as prednisone, are the standard initial treatment for adults with primary FSGS and nephrotic syndrome [4]. Unlike many other conditions where steroids are taken for a few days, FSGS often requires a prolonged course—sometimes up to 16 weeks—to see if the kidneys will respond [5].
- Safety Note: Steroids can cause infection, elevated blood sugar, increased blood pressure, mood and sleep changes, bone effects, gastrointestinal issues, and eye complications. An initial trial and taper are individualized, and you should never stop taking steroids abruptly.
- Second-Line: Calcineurin Inhibitors (CNIs): If the disease is steroid-resistant (does not improve with steroids) or steroid-dependent (returns as soon as steroids are lowered), doctors often switch to a class of drugs called calcineurin inhibitors, such as cyclosporine or tacrolimus [6][7].
- Safety Note: Tacrolimus and cyclosporine require drug-level monitoring. Side effects can include kidney toxicity, high blood pressure, and tremors. Report adverse effects to your doctor rather than altering the dose independently.
- The Goal: The main goal is to achieve remission, where protein levels in the urine drop significantly. Remission is the strongest indicator that your kidneys will remain healthy over the long term [8].
Treating Secondary and Genetic FSGS
For people with Secondary FSGS (caused by things like obesity, high blood pressure, or viruses) or Genetic FSGS, the problem is usually structural or related to an underlying stressor rather than an immune attack [9].
- Avoiding Immunosuppression: In these cases, steroids and other immune-suppressing drugs are generally avoided because they expose patients to toxicity without clear benefit [2][10]. However, treatment decisions belong with a nephrologist, and an alternative immune indication or later evidence of primary FSGS can change this decision.
- Supportive Care: Instead, the focus is on “supportive care” to protect the remaining healthy filters and reduce the workload on the kidneys [8]. This includes:
Essential Supportive Care for All FSGS
Regardless of the cause, most patients with FSGS will receive supportive therapy to slow the progression of kidney disease [8].
1. RAAS Blockade (ACE Inhibitors and ARBs)
Medications known as ACE inhibitors (like lisinopril) or ARBs (like losartan) are often the cornerstone of FSGS management [11]. These drugs do two critical things:
- They lower the pressure inside the kidney’s filtering units [8].
- They reduce the amount of protein leaking into the urine, which helps prevent further scarring (fibrosis) [8].
Note: These medications are not appropriate for everyone, such as patients with acute kidney injury, severe hyperkalemia, symptomatic low blood pressure, or pregnancy. These two types of drugs should not be taken together, and your doctor will monitor your creatinine and potassium closely after initiation or dose changes [11].
2. SGLT2 Inhibitors
Current practice increasingly includes a newer class of drugs called SGLT2 inhibitors (originally for diabetes) for selected patients. They have been shown to provide significant kidney protection and reduce protein loss in proteinuric chronic kidney disease, which can include FSGS [12]. Eligibility depends on eGFR, albuminuria, volume status, and other factors. Risks include genital infections, volume depletion, and rare ketoacidosis.
3. Diuretics
If you have significant swelling (edema), your doctor will prescribe “water pills” (diuretics) to help your body get rid of excess fluid and salt [8]. Diuretics can cause dehydration and electrolyte abnormalities if overused. These medicines are prescribed and adjusted by your care team rather than self-started or increased.
Why the “Wait and See” Approach Matters
If your diagnosis is FSGS of Undetermined Cause, your doctor may choose to start with supportive care (like blood pressure medication) rather than steroids [1]. This allows them to monitor how your body reacts before committing to the potential side effects of stronger immunosuppressants. Correctly identifying the “type” of FSGS is the most important step in ensuring you get the right treatment at the right time [2].
Common questions in this guide
How is treatment chosen for FSGS?
Why might I need steroids for FSGS, and how long could I take them?
What happens if steroids do not work or FSGS returns when the dose is lowered?
How do ACE inhibitors and ARBs help with FSGS?
Can SGLT2 inhibitors help people with FSGS?
What can help control swelling caused by FSGS?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Focal segmental glomerulosclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on the KDIGO 2021 criteria, am I being treated for primary, secondary, or genetic FSGS?
- 2.If I am starting high-dose steroids, what is the planned duration, and what signs of 'steroid resistance' will you be looking for?
- 3.What specific blood tests—such as potassium and creatinine—will you use to monitor my kidney function while I am on an ACE inhibitor or ARB?
- 4.If I don't respond to steroids, would a calcineurin inhibitor (CNI) be the next step, or should we revisit the diagnosis with genetic testing?
- 5.What are the long-term risks of immunosuppression for me, and how will we balance those against the goal of reducing my proteinuria?
References
References (12)
- 1
Indications for genetic testing in adults with focal segmental glomerulosclerosis.
Pilco-Terán M, Shabaka A, Furlano M, et al.
Nefrologia 2025; (45(2)):135-149 doi:10.1016/j.nefroe.2025.02.001.
PMID: 39952830 - 2
Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.
Mirioglu S, Daniel-Fischer L, Berke I, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (39(4)):569-580 doi:10.1093/ndt/gfae025.
PMID: 38341276 - 3
Focal Segmental Glomerulosclerosis.
Rosenberg AZ, Kopp JB
Clinical journal of the American Society of Nephrology : CJASN 2017; (12(3)):502-517 doi:10.2215/CJN.05960616.
PMID: 28242845 - 4
CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS).
Miao Z, Ertl LS, Newland D, et al.
PloS one 2018; (13(3)):e0192405 doi:10.1371/journal.pone.0192405.
PMID: 29561839 - 5
Optimal management of primary focal segmental glomerulosclerosis in adults.
Beaudreuil S, Lorenzo HK, Elias M, et al.
International journal of nephrology and renovascular disease 2017; (10()):97-107 doi:10.2147/IJNRD.S126844.
PMID: 28546764 - 6
Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades.
Beer A, Mayer G, Kronbichler A
BioMed research international 2016; (2016()):4192578 doi:10.1155/2016/4192578.
PMID: 27144166 - 7
Calcineurin Inhibitors With Reduced-Dose Steroids as First-Line Therapy for Focal Segmental Glomerulosclerosis.
Chávez-Mendoza CA, Niño-Cruz JA, Correa-Rotter R, et al.
Kidney international reports 2019; (4(1)):40-47 doi:10.1016/j.ekir.2018.08.010.
PMID: 30596167 - 8
Podocytopathies.
Kopp JB, Anders HJ, Susztak K, et al.
Nature reviews. Disease primers 2020; (6(1)):68 doi:10.1038/s41572-020-0196-7.
PMID: 32792490 - 9
Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective.
Shabaka A, Tato Ribera A, Fernández-Juárez G
Nephron 2020; (144(9)):413-427 doi:10.1159/000508099.
PMID: 32721952 - 10
Management of steroid-resistant nephrotic syndrome in children and adolescents.
Tullus K, Webb H, Bagga A
The Lancet. Child & adolescent health 2018; (2(12)):880-890 doi:10.1016/S2352-4642(18)30283-9.
PMID: 30342869 - 11
Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis.
Campbell KN, Pennese N, Zaffalon A, et al.
Kidney medicine 2022; (4(5)):100457 doi:10.1016/j.xkme.2022.100457.
PMID: 35518835 - 12
[Classical nephroprotection: Renin angiotensin aldosterone system inhibitors].
Egocheaga MI, Drak Y, Otero V
Semergen 2023; (49 Suppl 1()):102018 doi:10.1016/j.semerg.2023.102018.
PMID: 37355297
This page is for informational purposes only and does not constitute medical advice. Your nephrologist can determine the cause of your FSGS and tailor treatment and monitoring to your kidney function, blood pressure, and lab results.